Scynexis takes out $60M loan ahead of expected approval; Compass Therapeutics acquires new bispecific antibody in buyout
As the PDUFA date for their vaginal yeast infections quickly approaches, Scynexis is taking out a loan to ensure it can hit the ground running …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
